Providing litigation support, expert review, and expert opinion services concerning biosimilars
Understandably, this section is much shorter – because so much of our litigation support and expert work is confidential.
MATRIX45 actively provides litigation support, expert review, and expert opinion services concerning biosimilars – an area in which we have been the acknowledged (and sometimes resented) pioneers since the first biosimilar approvals in Europe in the mid-2000s and now encompassing clients in Europe, the Americas, and Asia.
Focal areas include:
- public interest of biosimilar competition
- market entry and competition
- price/cost impact
- expanded patient access and equity
- modeling of variations in treatment regimens
- risk of failure modeling due to externalities
- patient preference and impact
Clients around the world
We also provide expert review and expert opinion on issues challenging our clients – in the US and globally. We have offered clients independent scientific and technical review, due diligence, and validation expertise as they appraise internal work or externally commissioned services.
Clients have retained us for:
- knowledge appraisal and synthesis
- options analysis
- opportunity and risk analysis
- market access strategy
- payer engagement
- economics
Representative publications
“A dyer who has found the means of producing a particular color with materials which cost half the price of those commonly made use of, may, with good management, enjoy the advantage of his discovery as long as he lives, and even leave it as a legacy to his posterity.”
— Adam Smith (1723-1790), father of modern economics, in The Wealth of Nations (1776)
matrix45.com 